Foscarbidopa/foslevodopa

Foscarbidopa/foslevodopa, sold under the brand name Vyalev, is a fixed-dose combination medication used for the treatment of Parkinson's disease. It is a combination of prodrugs for levodopa and carbidopa that is developed by AbbVie

The combination was refused approval by the US Food and Drug Administration (FDA) in 2023. It was approved for medical use in Canada in May 2023, and in Australia in March 2024.